Author:
Nieto Yago,Shpall Elizabeth J.
Reference219 articles.
1. Peters WP, Henner WD, Bast RC, Schnipper L, Frei E III. Novel toxicities associated with high dose combination alkylating agents in autologous bone marrow support. In: Dicke KA, Spitzer G, Zander AR, eds. Autologous Bone Marrow Transplantation: Proceedings of the First International Symposium. Houstin, TX: University of Texas Cancer Center, M.D. Anderson Hospital, 1986; pp 231–235.
2. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870–1879.
3. Damon LE, Hu WW, Stockerl-Goldstein KE, et al. High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: Experience in California. Biol Blood Marrow Transplant 2000; 6: 496–505.
4. Hryniuk W, Busch H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281–1288.
5. Hryniuk W, Frei E III, Wright FA. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: Summation dose-intensity. J Clin Oncol 1998; 16: 3137–3147.